RESUMEN
ETHNOPHARMACOLOGICAL RELEVANCE: Semen Cuscutae, called Tu-si-zi in Chinese, is a kind of dried mature seed in the Convolvulaceae family. It mainly distributes in China, Korea, Pakistan, Vietnam, India and Thailand. It is used as a kidney-tonifying drug for treatment of aging related diseases such as osteoporosis in traditional Chinese medicine. However, the exact mechanisms on bone resorption are poorly studied. AIM OF THE STUDY: The aim of this study was to investigate the potential effect of Semen Cuscutae on ovariectomy (OVX)-induced osteoporosis in mice and clarify the exact mechanisms by which Semen Cuscutae exert the anti-osteoporosis effect. MATERIALS AND METHODS: Qualitative and quantitative analyses of Semen Cuscutae were performed by UPLC-Q-TOF-MS and HPLC-MS/MS, respectively. Changes in bone mineral density (BMD) induced by OVX in mice were measured by dual-energy X-ray absorptiometry and micro-computed tomography (µCT). Tartrate-resistant acid phosphatase (TRAP) staining as well as hematoxylin and eosin (HE) staining were used to observe bone microarchitectural changes. ELISA kits were used to assess the therapeutic effects of Semen Cuscutae on the serum levels of osteoprotegerin (OPG), tartrate-resistant acid phosphatase 5b (TRACP-5b), and receptor activator of nuclear factor-κB (RANKL). The effect of Semen Cuscutae on primary cell viability was assessed using CCK-8 and anti-tartrate phosphatase assays. TRAP staining and actin ring staining were used to observe the effect of Semen Cuscutae on osteoclast differentiation. Western blotting was used to measure the effects of Semen Cuscutae on expressions of NFATC1, c-Src kinase, and c-fos. RESULTS: Results from UPLC-Q-TOF-MS showed that the main components of Semen Cuscutae were flavonoid compounds that included quercitrin, quercetin, hyperoside, caffeic acid, rutin, chlorogenic acid, luteolin, apigenin, kaempferol, isoquercetin, cryptochlorogenic acid, isorhamnetin-3-O-glucoside, and astragalin. After the Semen Cuscutae extract was orally administered to OVX mice, bone density increased (P < 0.01) and bone microstructure was significantly improved (P < 0.01 or 0.05). Additionally, Semen Cuscutae exhibited a significant descending effect in the levels of serum TRACP-5b and RANKL, while there was a significant increase in OPG in the Semen Cuscutae group compared with the OVX group, especially at high doses. Moreover, we found that increasing of c-fos, c-Src kinase, and NFATC1 protein expressions were reversed by Semen Cuscutae in vitro and in vivo. CONCLUSIONS: Our results showed that Semen Cuscutae exhibited anti-osteoporosis effects through the c-fos/c-Src kinase/NFATC1 signaling pathway.
Asunto(s)
Resorción Ósea , Medicamentos Herbarios Chinos/farmacología , Osteoporosis , Transducción de Señal/efectos de los fármacos , Absorciometría de Fotón/métodos , Animales , Conservadores de la Densidad Ósea/farmacología , Resorción Ósea/diagnóstico por imagen , Resorción Ósea/tratamiento farmacológico , Resorción Ósea/metabolismo , Proteína Tirosina Quinasa CSK/metabolismo , Ratones , Factores de Transcripción NFATC/metabolismo , Osteoclastos/efectos de los fármacos , Osteoclastos/fisiología , Osteoporosis/tratamiento farmacológico , Osteoporosis/metabolismo , Extractos Vegetales/farmacología , Proteínas Proto-Oncogénicas c-fos/metabolismo , Microtomografía por Rayos X/métodosRESUMEN
The aim of this study was to determine the effects of ß-hydroxy-ß-methylbutyrate (HMB) supplementation during pregnancy on postpartum bone tissue quality by assessing changes in trabecular and compact bone as well as in hyaline and epiphyseal cartilage. The experiment was carried out on adult 6-month-old female spiny mice (Acomys cahirinus) divided into three groups: pregnant control (PregCont), pregnant HMB-treated (supplemented with 0.02 g/kg b.w of HMB during the second trimester of pregnancy, PregHMB), and non-pregnant females (NonPreg). Cross-sectional area and cortical index of the femoral mid-shaft, stiffness, and Young modulus were significantly greater in the PregHMB group. Whole-bone mineral density was similar in all groups, and HMB supplementation increased trabecular number. Growth plate cartilage was the thinnest, while the articular cartilage was the thickest in the PregHMB group. HMB supplementation increased the content of proteoglycans in the articular cartilage and the percentage of immature collagen content in metaphyseal trabeculae and compact bone. In summary, dietary HMB supplementation during the second trimester of pregnancy intensifies bone metabolic processes and prevents bone loss during pregnancy.
Asunto(s)
Resorción Ósea/tratamiento farmacológico , Resorción Ósea/prevención & control , Valeratos/uso terapéutico , Animales , Peso Corporal/efectos de los fármacos , Resorción Ósea/diagnóstico por imagen , Hueso Esponjoso/diagnóstico por imagen , Hueso Esponjoso/efectos de los fármacos , Hueso Esponjoso/patología , Cartílago Articular/diagnóstico por imagen , Cartílago Articular/efectos de los fármacos , Cartílago Articular/patología , Colágeno/metabolismo , Epífisis/efectos de los fármacos , Epífisis/patología , Femenino , Fémur/diagnóstico por imagen , Fémur/efectos de los fármacos , Fémur/patología , Murinae , Embarazo , Proteoglicanos/metabolismo , Valeratos/farmacología , Microtomografía por Rayos XRESUMEN
The human body is comprised of hundreds of bones, which are constantly regenerated through the interactions of two cell types: osteoblasts and osteoclasts. Given the difficulty of analyzing their intravital dynamics, we have developed a system for intravital imaging of the bone marrow cavity using two-photon microscopy, to visualize the dynamic behaviors of living bone cells without sectioning. Combined with the newly developed chemical fluorescent probes to detect localized acidification caused by osteoclasts, we identified two distinct functional states of mature osteoclasts, i.e., "bone-resorptive" and "non-resorptive". Here, we focus on the dynamics and functions of bone cells within the bone marrow cavity and discuss how this novel approach has been applied to evaluate the mechanisms of action of drugs currently in clinical use. We further introduce our recent study that identified arthritis-associated osteoclastogenic macrophages in inflamed synovium and revealed their differentiation trajectory into the pathological osteoclasts, which together represent to a new paradigm in bone research.
Asunto(s)
Médula Ósea/diagnóstico por imagen , Resorción Ósea/diagnóstico por imagen , Osteoclastos/metabolismo , Animales , Artritis/metabolismo , Médula Ósea/metabolismo , Resorción Ósea/metabolismo , Diferenciación Celular , Colorantes Fluorescentes/química , Homeostasis , Humanos , Macrófagos/metabolismo , Microscopía de Fluorescencia por Excitación Multifotónica/métodos , Imagen Óptica/métodosRESUMEN
With the aging of the population and the extension of life expectancy, osteoporosis is becoming a global epidemic. Although there are several drugs used to treat osteoporosis in clinical practice, such as parathyroid hormone or bisphosphonates, they all have some serious side effects. Therefore, a safer drug is called for osteoporosis, especially for the prevention in the early stage of the disease, not only the treatment in the later stage. Panax notoginseng saponin (PNS), a traditional Chinese herb, has been used as anti-ischemic drug due to its function on improving vascular circulation. In order to verify whether Panax notoginseng saponins (PNS) could be used to prevent osteoporosis, ovariectomy (OVX) was induced in female C57BL/C6J mice, followed by orally administration with 40 mg/kg/d, 80 mg/kg/d, and 160 mg/kg/d of three different dosages of PNS for 9 weeks. Serum biochemical analysis, micro-CT, histological evaluation, and immunostaining of markers of osteogenesis and angiogenesis were performed in the sham, osteoporotic (OVX), and treatment (OVX+PNS) groups. Micro-CT and histological evaluation showed that compared to sham group, the bone mass of OVX group reduced significantly, while it was significantly restored in the moderate-dose PNS (40 mg/kg and 80 mg/kg) treatment groups. The expression of CD31 and osteocalcin (OCN) in the bone tissue of treatment group also increased, suggesting that PNS activated osteogenesis and angiogenesis, which subsequently increased the bone mass. These results confirmed the potential function of PNS on the prevention of osteoporosis. However, in the high dose of PNS (160 mg/kg) group, the antiosteoportic effect had been eliminated, which also suggested the importance of proper dose of PNS for the prevention and treatment of osteoporosis in postmenopausal women.
Asunto(s)
Resorción Ósea/tratamiento farmacológico , Neovascularización Fisiológica , Osteoporosis/tratamiento farmacológico , Panax notoginseng/química , Saponinas/uso terapéutico , Animales , Biomarcadores/sangre , Peso Corporal/efectos de los fármacos , Resorción Ósea/sangre , Resorción Ósea/complicaciones , Resorción Ósea/diagnóstico por imagen , Modelos Animales de Enfermedad , Células Endoteliales/efectos de los fármacos , Células Endoteliales/metabolismo , Imagenología Tridimensional , Ratones Endogámicos C57BL , Neovascularización Fisiológica/efectos de los fármacos , Osteoblastos/efectos de los fármacos , Osteoblastos/metabolismo , Osteoporosis/sangre , Osteoporosis/complicaciones , Osteoporosis/diagnóstico por imagen , Saponinas/farmacología , Microtomografía por Rayos XRESUMEN
Compared to other materials such as 45S5 bioactive glass (BG), ß-tricalcium phosphate (ß-TCP)-based bone substitutes such as Vitoss show limited material-driven stimulation of osteogenesis and/or angiogenesis. The unfavorable degradation kinetics of ß-TCP-based bone substitutes may result in an imbalance between resorption and osseous regeneration. Composite materials like Vitoss BA (Vitoss supplemented with 20 wt % 45S5-BG particles) might help to overcome these limitations. However, the influence of BG particles in Vitoss BA compared to unsupplemented Vitoss on osteogenesis, resorption behavior, and angiogenesis is not yet described. In this study, Vitoss and Vitoss BA scaffolds were seeded with human mesenchymal stromal cells before subcutaneous implantation in immunodeficient mice for 10 weeks. Scaffold resorption was monitored by micro-computed tomography, while osteoid formation and vascularization were assessed by histomorphometry and gene expression analysis. Whilst slightly more osteoid and improved angiogenesis were found in Vitoss BA, maturation of the osteoid was more advanced in Vitoss scaffolds. The volume of Vitoss implants decreased significantly, combined with a significantly increased presence of resorbing cells, whilst the volume remained stable in Vitoss BA scaffolds. Future studies should evaluate the interaction of 45S5-BG with resorbing cells and bone precursor cells in greater detail to improve the understanding and application of ß-TCP/45S5-BG composite bone substitute materials.
Asunto(s)
Resorción Ósea/tratamiento farmacológico , Sustitutos de Huesos/uso terapéutico , Fosfatos de Calcio/uso terapéutico , Cerámica/uso terapéutico , Silicatos/uso terapéutico , Adulto , Animales , Resorción Ósea/diagnóstico por imagen , Diferenciación Celular/efectos de los fármacos , Cerámica/farmacología , Femenino , Vidrio , Humanos , Cinética , Masculino , Ratones SCID , Persona de Mediana Edad , Neovascularización Fisiológica/efectos de los fármacos , Osteogénesis/efectos de los fármacos , Andamios del Tejido/química , Microtomografía por Rayos X , Adulto JovenRESUMEN
Postoperative bone loss and increased fracture risk associated with Roux-en-Y gastric bypass (RYGB) have been attributed to vitamin D/calcium malabsorption and resultant secondary hyperparathyroidism (HPT). Adequate vitamin D supplementation (VDS), particularly in an older female population, reduces incidence of secondary HPT but the effect on bone loss and fracture risk remains unclear. To investigate whether VDS corrects the RYGB bone phenotype, 41 obese adult female rats were randomized to RYGB with 1000â¯IU (R1000) or 5000â¯IU (R5000) vitamin D/kg food or a sham surgical procedure with either paired (PF) or ad libitum (AL) feeding. Bone turnover markers, urinary calcium/creatinine ratio (CCR), and serum calciotropic and gut hormones were assessed throughout a 14-week postoperative period. Femurs were analyzed by micro-computed tomography (µCT), three-point bending test, and histomorphometry. 1000â¯IU animals had low 25hydroxyvitamin D (25(OH)D), high serum parathyroid hormone (PTH), and very low urine CCR levels. 5000â¯IU corrected the 25(OH)D and secondary HPT but did not increase urine CCR or serum levels of 1,25dihydroxyvitamin D (1,25(OH)D) significantly between RYGB groups. Compared to sham animals at 14â¯weeks, RYGB animals had significantly higher serum osteocalcin (OCN) and C-terminal telopeptide (CTX) levels. The gut hormone peptide tyrosine tyrosine hormone (PYY) was higher in the RYGB groups, and leptin was lower. µCT and biomechanical testing revealed RYGB females had decreased cortical and trabecular bone volume and weaker, stiffer bone than controls. Histomorphometry showed decreased bone volume and increased osteoid volume with increased mineral apposition rate in RYGB compared to controls. No differences in bone phenotype were identified between 1000â¯IU and 5000â¯IU groups, and osteoclast numbers were comparable across all four groups. Thus, in our model, 5000â¯IU VDS corrected vitamin D deficiency and secondary HPT but did not rescue RYGB mineralization rate nor the osteomalacia phenotype. Longer studies in this model are required to evaluate durability of these detrimental effects. Our findings not only underscore the importance of lifelong repletion of both calcium and vitamin D but also suggest that additional factors affect skeletal health in this population.
Asunto(s)
Resorción Ósea/tratamiento farmacológico , Resorción Ósea/etiología , Suplementos Dietéticos , Derivación Gástrica/efectos adversos , Vitamina D/uso terapéutico , Animales , Biomarcadores/metabolismo , Fenómenos Biomecánicos/efectos de los fármacos , Peso Corporal , Remodelación Ósea/efectos de los fármacos , Resorción Ósea/sangre , Resorción Ósea/diagnóstico por imagen , Calcio/metabolismo , Relación Dosis-Respuesta a Droga , Conducta Alimentaria , Femenino , Fémur/diagnóstico por imagen , Fémur/efectos de los fármacos , Fémur/fisiopatología , Hormonas/metabolismo , Ratas Sprague-Dawley , Vitamina D/farmacología , Microtomografía por Rayos XRESUMEN
Traditional Chinese herbal medicine plays a role as an alternative method in treating many diseases, such as postmenopausal osteoporosis (POP). Gushukang (GSK) granules, a marketed prescription in China, have bone-protective effects in treating POP. Before administration to the body, one standard preparation procedure is commonly required, which aims to promote the release of active constituents from raw herbs and enhance the pharmacological effects as well as therapeutic outcomes. This study proposes a detailed protocol for using GSK granules in in vivo and in vitro experimental assays. The authors first provide a detailed protocol to calculate the animal-appropriate dosages of granules for in vivo investigation: weighing, dissolving, storage, and administration. Second, this article describes protocols for micro-CT scanning and the measurement of bone parameters. Sample preparation, protocols for running the micro-CT machine and quantification of bone parameters were evaluated. Third, serum-containing GSK granules are prepared, and drug-containing serum is extracted for in vitro osteoclastogenesis and osteoblastogenesis. GSK granules were intragastrically administered twice per day to rats for three consecutive days. Blood was then collected, centrifuged, inactivated, and filtered. Finally, serum was diluted and used for performing osteoclastogenesis and osteoblastogenesis. The protocol described here can be considered a reference for pharmacological investigations of herbal prescription medicines, such as granules.
Asunto(s)
Medicamentos Herbarios Chinos/uso terapéutico , Animales , Resorción Ósea/diagnóstico por imagen , Resorción Ósea/tratamiento farmacológico , Resorción Ósea/patología , Medicamentos Herbarios Chinos/farmacología , Femenino , Humanos , Ratones Endogámicos C57BL , Osteoblastos/efectos de los fármacos , Osteoclastos/efectos de los fármacos , Osteogénesis/efectos de los fármacos , OvariectomíaRESUMEN
Sudden respiratory distress in association with severe weight loss are unusual features of systemic sclerosis (SSc). We report the case of a 56-year-old Caucasian woman with a 9-year history of a diffuse form of SSc who presented with acute stridor due to vocal cord paralysis and required an emergency tracheostomy. She had sought medical attention only after 4 years of disease onset, presenting with a mask-like face, diffuse skin thickening, acro-osteolysis and severe interstitial lung disease. Even though skin tightness improved after immunosuppressive treatment, several spontaneous facial fractures and episodes of dysphagia and choking occurred in the years that followed. At the time of stridor, she was severely malnourished and a percutaneous endoscopic gastrostomy was required for feeding. Permanent vocal cord damage in combination with severe loco-regional bone resorption resulted in severe disability and impaired nutrition. We hereby highlight the features of SSc for which therapy remains challenging.
Asunto(s)
Resorción Ósea/etiología , Resorción Ósea/patología , Mandíbula/patología , Esclerodermia Sistémica/complicaciones , Parálisis de los Pliegues Vocales/etiología , Anticuerpos Monoclonales Humanizados/uso terapéutico , Resorción Ósea/diagnóstico por imagen , Calcio/uso terapéutico , Diagnóstico Diferencial , Suplementos Dietéticos , Femenino , Humanos , Desnutrición/diagnóstico , Desnutrición/etiología , Desnutrición/terapia , Mandíbula/diagnóstico por imagen , Persona de Mediana Edad , Esclerodermia Sistémica/patología , Esclerodermia Sistémica/terapia , Tomografía Computarizada por Rayos X , Traqueostomía , Vitamina D/uso terapéutico , Parálisis de los Pliegues Vocales/terapiaRESUMEN
Denosumab is an anti-RANKL antibody that is commonly used for the treatment of osteoporosis; in oncology, bisphosphonates and denosumab have become the standard therapies for the treatment and prevention of skeletal complications in patients with myeloma and solid tumors. In recent years, excessive bone remodeling following the discontinuation of denosumab has raised concerns. Several cases of hypercalcemia have been reported after the discontinuation of high-dose denosumab (120â¯mg every 4â¯weeks), mainly in children. In this study, we report a new case of severe refractory hypercalcemia in a 54-year-old woman who received high-dose denosumab for 5â¯years as an adjuvant therapy for breast cancer. She is currently in remission and undergoing treatment with anastrazole, an aromatase inhibitor. The peculiarities of this case are the presence of associated bone pain with subperiosteal bone resorption on hand X-rays, and diffuse, long bone diaphyseal uptake on a bone scan. Hyperparathyroidism has been ruled out, and existing evidence suggests that this high-level of bone remodeling could be due to a rebound hyperactivation of the RANKL pathway. In addition to rehydration, repeated use of i.v. bisphosphonates was required to control recurrent hypercalcemia. As hypercalcemia is a serious metabolic complication, a gradual dose reduction should be considered when interruption of high dose denosumab therapy is planned.
Asunto(s)
Resorción Ósea/complicaciones , Hipercalcemia/complicaciones , Ligando RANK/metabolismo , Enfermedad Aguda , Resorción Ósea/diagnóstico por imagen , Resorción Ósea/tratamiento farmacológico , Huesos/diagnóstico por imagen , Huesos/patología , Femenino , Humanos , Hipercalcemia/diagnóstico por imagen , Hipercalcemia/tratamiento farmacológico , Persona de Mediana Edad , Pamidronato/uso terapéuticoRESUMEN
OBJECTIVE: Food-derived peptides have been reported to exhibit antibacterial activity against periodontal pathogenic bacteria. However, no effect has been shown on inflammation and bone resorption in periodontal pathology. The overall objective of the current study was to investigate how rice peptides influence biological defense mechanisms against periodontitis-induced inflammatory bone loss, and identify their novel functions as a potential anti-inflammatory drug. DESIGN: The expression of inflammatory and osteoclast-related molecules was examined in mouse macrophage-derived RAW 264.7 cell cultures using qPCR. Subsequently, the effect of these peptides on inflammatory bone loss in mouse periodontitis was examined using a mouse model of tooth ligation. Briefly, periodontal bone loss was induced for 7 days in mice by ligating the maxillary second molar and leaving the contralateral tooth un-ligated (baseline control). The mice were microinjected daily with the peptide in the gingiva until the day before euthanization. One week after the ligation, TRAP-positive multinucleated cells (MNCs) were enumerated from five random coronal sections of the ligated sites in each mouse. RESULTS: Rice peptides REP9 and REP11 significantly inhibited transcription activity of inflammatory and osteoclast-related molecules. Local treatment with the rice peptides, in mice subjected to ligature-induced periodontitis, inhibited inflammatory bone loss, explaining the decreased numbers of osteoclasts in bone tissue sections. CONCLUSION: Therefore, these data suggested that the rice peptides possess a protective effect against periodontitis.
Asunto(s)
Pérdida de Hueso Alveolar/tratamiento farmacológico , Antibacterianos/farmacología , Endospermo/química , Oryza/química , Péptidos/antagonistas & inhibidores , Periodontitis/tratamiento farmacológico , Extractos Vegetales/farmacología , Pérdida de Hueso Alveolar/diagnóstico por imagen , Pérdida de Hueso Alveolar/patología , Animales , Antibacterianos/administración & dosificación , Antibacterianos/uso terapéutico , Resorción Ósea/diagnóstico por imagen , Resorción Ósea/tratamiento farmacológico , Resorción Ósea/patología , Supervivencia Celular/efectos de los fármacos , Citocinas/metabolismo , Modelos Animales de Enfermedad , Encía/efectos de los fármacos , Inflamación , Ligadura , Masculino , Ratones , Ratones Endogámicos BALB C , Diente Molar , Osteoclastos/efectos de los fármacos , Péptidos/administración & dosificación , Péptidos/uso terapéutico , Periodontitis/diagnóstico por imagen , Periodontitis/patología , Extractos Vegetales/uso terapéutico , Proteínas de Plantas/administración & dosificación , Proteínas de Plantas/antagonistas & inhibidores , Proteínas de Plantas/uso terapéutico , Células RAW 264.7 , Microtomografía por Rayos X/métodosRESUMEN
BACKGROUND: Aromatase inhibitors (AI) have been established as the gold-standard therapy for postmenopausal patients. Worldwide, adjuvant denosumab at a dose of 60 mg twice per year reduces the risk of clinical fractures in postmenopausal patients with breast cancer who received AI. However, the efficacy of denosumab in the treatment of AI-associated bone loss had not been prospectively evaluated in Japan. Previously, we reported the 12-month effect of denosumab in Japanese patients for the first time; the primary endpoint was the change in the percentage of bone mineral density (BMD) of the lumbar spine from baseline to 12 months. METHODS: This secondary follow-up study prospectively evaluated the change in the percentage of BMD of the lumbar spine from baseline to 24 months. Postmenopausal women with early-stage, histologically confirmed, hormone receptor-positive, invasive breast cancer who were receiving or scheduled to receive AI were included. Denosumab was administered subcutaneously on day 1 of the study and then 6, 12, 18, and 24 months. The lumbar spine and bilateral femoral neck BMD was measured at baseline and 6, 12, 18, and 24 months. RESULTS: At 18 and 24 months, the lumbar spine BMD increased by 5.9 and 7.0%, respectively. The femoral neck BMD also increased. Grade ≥ 2 hypocalcemia, osteonecrosis of the jaw, and atypical femoral fractures did not occur. CONCLUSIONS: Our prospective study showed that semiannual treatment with denosumab was associated with continuously increased BMD in Japanese women receiving adjuvant AI therapy for up to 24 months, regardless of prior AI treatment.
Asunto(s)
Antineoplásicos Hormonales/efectos adversos , Inhibidores de la Aromatasa/efectos adversos , Conservadores de la Densidad Ósea/farmacología , Resorción Ósea/tratamiento farmacológico , Neoplasias de la Mama/terapia , Denosumab/farmacología , Absorciometría de Fotón , Anciano , Densidad Ósea/efectos de los fármacos , Conservadores de la Densidad Ósea/uso terapéutico , Resorción Ósea/inducido químicamente , Resorción Ósea/diagnóstico por imagen , Quimioterapia Adyuvante/efectos adversos , Quimioterapia Adyuvante/métodos , Denosumab/uso terapéutico , Esquema de Medicación , Femenino , Estudios de Seguimiento , Humanos , Inyecciones Subcutáneas , Japón , Vértebras Lumbares/diagnóstico por imagen , Persona de Mediana Edad , Posmenopausia , Estudios Prospectivos , Resultado del TratamientoRESUMEN
Background: Because orthodontic tooth movement is dependent upon osteoclast-mediated resorption of alveolar bone adjacent to the pressure side of tooth roots, biologic mediators that regulate osteoclasts can be utilized to control tooth movement. Objectives: To develop a novel method to locally enhance orthodontic anchorage. Methods: We encapsulated osteoprotegerin (OPG) in polymer microspheres and tested the effectiveness of microsphere encapsulated versus non-encapsulated OPG for enhancing orthodontic anchorage in a rodent model of tooth movement. A single injection of 1 mg/kg non-encapsulated or microsphere encapsulated OPG was delivered into the palatal mucosa mesial to the first maxillary molar 1 day prior to tooth movement. A positive control group received injections of 5 mg/kg non-encapsulated OPG every 3 days during tooth movement. After 28 days of tooth movement, hemi-maxillae and femurs were dissected. Molar mesial and incisor distal tooth movement was measured using stone casts that were scanned and magnified. Local alveolar, distant femur bone, and tooth root volumes were analyzed by micro computed tomography. Serum OPG levels were measured by ELISA. Osteoclast numbers were quantified by histomorphometry. Results: The single injection of microsphere encapsulated OPG significantly enhanced orthodontic anchorage, while the single injection of non-encapsulated OPG did not. Injection of encapsulated OPG inhibited molar mesial movement but did not inhibit incisor tooth movement, and did not alter alveolar or femur bone volume fraction, density, or mineral content. Multiple injections of 5 mg/kg non-encapsulated OPG enhanced orthodontic anchorage, but also inhibited incisor retraction and altered alveolar and femur bone quality parameters. Increased OPG levels were found only in animals receiving multiple injections of non-encapsulated 5 mg/kg OPG. Osteoclast numbers were higher upon tooth movement in animals that did not receive OPG. Osteoclast numbers in OPG injected animals were variable within groups. Conclusions: Microsphere encapsulation of OPG allows for controlled drug release, and enhances site-specific orthodontic anchorage without systemic side effects. With additional refinements, this drug delivery system could be applicable to a broad array of potential biologic orthodontic therapeutics.
Asunto(s)
Resorción Ósea/prevención & control , Métodos de Anclaje en Ortodoncia/métodos , Osteoprotegerina/administración & dosificación , Técnicas de Movimiento Dental/métodos , Animales , Resorción Ósea/diagnóstico por imagen , Sistemas de Liberación de Medicamentos , Evaluación Preclínica de Medicamentos , Fémur/diagnóstico por imagen , Fémur/efectos de los fármacos , Incisivo/diagnóstico por imagen , Incisivo/efectos de los fármacos , Masculino , Microesferas , Diente Molar/diagnóstico por imagen , Diente Molar/efectos de los fármacos , Osteoclastos/efectos de los fármacos , Osteoprotegerina/uso terapéutico , Ratas Sprague-Dawley , Microtomografía por Rayos XRESUMEN
BACKGROUND: The purpose of this study was to evaluate the efficacy of denosumab or zoledronic acid (ZA) using symptomatic skeletal events (SSEs) as the primary endpoint in Asian postmenopausal women with oestrogen-receptor-positive advanced breast cancer. METHODS: Asian postmenopausal women with oestrogen-receptor-positive advanced breast cancer receiving subcutaneous denosumab 120 mg Q4W, or intravenous ZA 4 mg Q4W until the primary analysis cut-off date were retrospectively analysed in the Hong Kong Practice-Based Cancer Research Center(HKCRC) from March 2011 to March 2013. The time to first on-study SSE that was assessed either clinically or through routine radiographic scans was the primary endpoint. RESULTS: 242 patients received denosumab or ZA treatment (n = 120, mean age of 64.9 years (SD 3.01) and n = 122, 65.4 years (3.44), respectively). The median times to first on-study SSE were 14.7 months (12.9-45.6) and 11.7 months (9.9-45.6) for denosumab and ZA, respectively (hazard ratio, HR 0.44, 95% CI 0.71-2.95; p = 0·0002). Compared with the ZA group, denosumab-treated patients had a significantly delayed time to first SSE (HR 0.65 [95% CI 0.29-1.45], p < 0.0001). An increased incidence of SSE was found in the 16-month follow-up with rates of 2.1 and 10.7% for denosumab and ZA, respectively (P = 0.033). The difference persisted with time with rates of 8.3 and 17.2% at the final follow-up, respectively (P < 0.05). CONCLUSION: In postmenopausal women aged ≥60 years with oestrogen-receptor-positive advanced breast cancer, denosumab significantly reduced the risk of developing SSEs compared with ZA. The findings of this pilot trial justify a larger study to determine whether the result is more generally applicable to a broader population.
Asunto(s)
Conservadores de la Densidad Ósea/uso terapéutico , Resorción Ósea/prevención & control , Neoplasias de la Mama/terapia , Denosumab/uso terapéutico , Ácido Zoledrónico/uso terapéutico , Anciano , Antineoplásicos Hormonales/efectos adversos , Pueblo Asiatico , Densidad Ósea/efectos de los fármacos , Densidad Ósea/efectos de la radiación , Resorción Ósea/diagnóstico por imagen , Resorción Ósea/etiología , Neoplasias de la Mama/complicaciones , Neoplasias de la Mama/patología , Quimioterapia Adyuvante/efectos adversos , Femenino , Estudios de Seguimiento , Hong Kong/epidemiología , Humanos , Incidencia , Mastectomía , Persona de Mediana Edad , Posmenopausia , Radioterapia Adyuvante/efectos adversos , Receptores de Estrógenos/metabolismo , Estudios Retrospectivos , Factores de Tiempo , Resultado del TratamientoRESUMEN
The objective of the present study was to assess hard and soft tissue around dental implants made of three different materials with microgrooves on the collar surface. Microgrooved implants were inserted in the mandibles of five male beagles. Implants were made of three kinds of material; titanium (Ti), yttria-stabilized tetragonal zirconia polycrystals (Y-TZP) and ceria partially stabilized zirconia/alumina nanocomposite (Ce-TZP/Al2O3). The animals were euthanatized at three months after implantation, and harvested tissue was analyzed by means of histology. All kinds of implant were osseointegrated, and there were no significant differences in any histomorphometric parameters among the three groups of microgrooved implants made of different materials. Within the limitations of this study, implants with microgrooves integrated into the surrounding bone tissue, without statistically significant differences among the three tested materials, Ti, Y-TZP, and Ce-TZP/Al2O3.
Asunto(s)
Óxido de Aluminio/química , Cerio/química , Implantación Dental Endoósea , Implantes Dentales , Diseño de Prótesis Dental , Titanio/química , Itrio/química , Circonio/química , Animales , Resorción Ósea/diagnóstico por imagen , Perros , Implantes Experimentales , Masculino , Mandíbula/cirugía , Ensayo de Materiales , Microscopía Electrónica de Rastreo , Modelos Animales , Nanocompuestos , Oseointegración , Propiedades de Superficie , Microtomografía por Rayos XRESUMEN
Metabolic syndrome (MetS) is associated with osteoporosis due to the underlying inflammatory and hormonal changes. Annatto tocotrienol has been shown to improve medical complications associated with MetS or bone loss in animal studies. This study aimed to investigate the effects of annatto tocotrienol as a single treatment for MetS and osteoporosis in high-carbohydrate high-fat (HCHF) diet-induced MetS animals. Three-month-old male Wistar rats were randomly divided into five groups. The baseline group was euthanized at the onset of the study. The normal group received standard rat chow and tap water. The remaining groups received HCHF diet and treated with three different regimens orally daily: (a) tocopherol-stripped corn oil (the vehicle of tocotrienol), (b) 60â¯mg/kg annatto tocotrienol, and (c) 100â¯mg/kg annatto tocotrienol. At the end of the study, measurements of MetS parameters, body compositions, and bone mineral density were performed in animals before sacrifice. Upon euthanasia, blood and femur of the rats were harvested for the evaluations of bone microstructure, biomechanical strength, remodelling activities, hormonal changes, and inflammatory response. Treatment with annatto tocotrienol improved all MetS parameters (except abdominal obesity), trabecular bone microstructure, bone strength, increased osteoclast number, normalized hormonal changes and inflammatory response in the HCHF animals. In conclusion, annatto tocotrienol is a potential agent for managing MetS and osteoporosis concurrently. The beneficial effects of annatto tocotrienol may be attributed to its ability to prevent the hormonal changes and pro-inflammatory state in animals with MetS.
Asunto(s)
Bixaceae/química , Resorción Ósea/tratamiento farmacológico , Síndrome Metabólico/tratamiento farmacológico , Tocotrienoles/uso terapéutico , Adiponectina/metabolismo , Animales , Resorción Ósea/complicaciones , Resorción Ósea/diagnóstico por imagen , Hueso Esponjoso/diagnóstico por imagen , Hueso Esponjoso/efectos de los fármacos , Hueso Esponjoso/patología , Carotenoides/administración & dosificación , Carotenoides/uso terapéutico , Dieta Alta en Grasa , Carbohidratos de la Dieta , Hiperglucemia/complicaciones , Hiperglucemia/tratamiento farmacológico , Hipertensión/complicaciones , Hipertensión/tratamiento farmacológico , Inflamación/patología , Leptina/metabolismo , Masculino , Síndrome Metabólico/complicaciones , Síndrome Metabólico/diagnóstico por imagen , Osteoblastos/efectos de los fármacos , Osteoblastos/metabolismo , Extractos Vegetales/administración & dosificación , Extractos Vegetales/uso terapéutico , Ratas Wistar , Tocotrienoles/administración & dosificación , Tocotrienoles/farmacología , Microtomografía por Rayos XRESUMEN
PURPOSE: Premenopausal women receiving chemotherapy or endocrine treatment for early breast cancer are at increased risk for cancer treatment induced bone loss (CTIBL). The aim of the randomized, double-blind ProBONE II trial was to investigate whether a 2-year adjuvant treatment with 4â¯mg intravenous zoledronic acid (ZOL) every 3â¯months versus placebo would prevent CTIBL after a five-year period. METHODS: Thirty-one of the 34 participants in the ZOL arm and thirty-four of the 36 participants in the placebo arm were followed-up to the 5-year visit and completed the study as planned. The changes in Bone Mass Density (BMD) were assessed at baseline and each visit after treatment initiation. RESULTS: After 24â¯months, BMD at the lumbar spine showed a 2.9% increase in patients treated with ZOL vs. a 7.1% decrease in placebo-treated participants compared to baseline (pâ¯<â¯0.001). Over the 60-month study period, we found a decrease of 2.2% vs. 7.3% in the BMD at the lumbar spine in patients receiving ZOL and placebo respectively (pâ¯<â¯0.001). Over the 60-month study period, BMD in the placebo arm showed a continuous decrease at all sites (pâ¯<â¯0001), whereas patients treated with ZOL reached baseline BMD-values at the femoral neck and total hip. CONCLUSIONS: In ProBone II, a 2-year treatment with ZOL 4â¯mg intravenous every 3â¯months prevented cancer treatment induced bone loss in premenopausal women with breast cancer and maintained the BMD up to 3â¯years post-treatment.
Asunto(s)
Antineoplásicos/efectos adversos , Conservadores de la Densidad Ósea/administración & dosificación , Resorción Ósea/prevención & control , Neoplasias de la Mama/tratamiento farmacológico , Premenopausia/efectos de los fármacos , Ácido Zoledrónico/administración & dosificación , Administración Intravenosa , Adulto , Antineoplásicos/administración & dosificación , Resorción Ósea/inducido químicamente , Resorción Ósea/diagnóstico por imagen , Resorción Ósea/epidemiología , Neoplasias de la Mama/diagnóstico por imagen , Neoplasias de la Mama/epidemiología , Método Doble Ciego , Quimioterapia Combinada , Femenino , Estudios de Seguimiento , Humanos , Persona de Mediana Edad , Premenopausia/fisiología , Estudios Prospectivos , Factores de Tiempo , Resultado del Tratamiento , Adulto JovenRESUMEN
Experimental autoimmune myasthenia gravis (EAMG), an animal model of myasthenia gravis (MG), can be induced in C57BL/6 (B6, H-2 b) mice by 2-3 injections with Torpedo californica AChR (tAChR) in complete Freund's adjuvant. Some EAMG mice exhibit weight loss with muscle weakness. The loss in body weight, which is closely associated with bone structure, is particularly evident in EAMG mice with severe muscle weakness. However, the relationship between muscle weakness and bone loss in EAMG has not been studied before. Recent investigations on bone have shed light on association of bone health and immunological states. It is possible that muscle weakness in EAMG developed by anti-tAChR immune responses might accompany bone loss. We determined whether reduced muscle strength associates with decreased bone mineral density (BMD) in EAMG mice. EAMG was induced by two injections at 4-week interval of tAChR and adjuvants in two different age groups. The first tAChR injection was either at age 8 weeks or at 15 weeks. We measured BMD at three skeletal sites, including femur, tibia, and lumbar vertebrae, using dual energy X-ray absorptiometry. Among these bone areas, femur of EAMG mice in both age groups showed a significant decrease in BMD compared to control adjuvant-injected and to non-immunized mice. Reduction in BMD in induced EAMG at a later-age appears to parallel the severity of the disease. The results indicate that anti-tAChR autoimmune response alone can reduce bone density in EAMG mice. BMD reduction was also observed in adjuvant-injected mice in comparison to normal un-injected mice, suggesting that BMD decrease can occur even when muscle activity is normal. Decreased BMD observed in both tAChR-injected and adjuvant-injected mice groups were discussed in relation to innate immunity and bone-related immunology involving activated T cells and tumour necrosis factor-related cytokines that trigger osteoclastogenesis and bone loss.
Asunto(s)
Densidad Ósea/inmunología , Resorción Ósea/patología , Debilidad Muscular/patología , Miastenia Gravis Autoinmune Experimental/patología , Absorciometría de Fotón , Factores de Edad , Animales , Resorción Ósea/inducido químicamente , Resorción Ósea/diagnóstico por imagen , Resorción Ósea/inmunología , Fémur/diagnóstico por imagen , Fémur/inmunología , Fémur/patología , Proteínas de Peces/administración & dosificación , Adyuvante de Freund/administración & dosificación , Vértebras Lumbares/diagnóstico por imagen , Vértebras Lumbares/inmunología , Vértebras Lumbares/patología , Masculino , Ratones , Ratones Endogámicos C57BL , Debilidad Muscular/inducido químicamente , Debilidad Muscular/diagnóstico por imagen , Debilidad Muscular/inmunología , Miastenia Gravis Autoinmune Experimental/inducido químicamente , Miastenia Gravis Autoinmune Experimental/diagnóstico por imagen , Miastenia Gravis Autoinmune Experimental/metabolismo , Receptores Colinérgicos/administración & dosificación , Índice de Severidad de la Enfermedad , Tibia/diagnóstico por imagen , Tibia/inmunología , Tibia/patología , Factores de Tiempo , Torpedo/metabolismoRESUMEN
The mechanism of bone substitute resorption involves two processes: solution-mediated and cell-mediated disintegration. In our previous animal studies, the main resorption process of beta-tricalcium phosphate (ß-TCP) was considered to be cell-mediated disintegration by TRAP-positive cells. Thus, osteoclast-mediated resorption of ß-TCP is important for enabling bone formation. We also report the results of treatment with ß-TCP graft in patients since 1989. Two to three weeks after implantation, resorption of ß-TCP occurred from the periphery, and then continued toward the center over time. Complete or nearly complete bone healing was achieved in most cases within a few years and was dependent upon the amount of implanted material, the patient's age, and the type of bone (cortical or cancellous). We have previously reported that an injectable complex of ß-TCP granules and collagen supplemented with rhFGF-2 enabled cortical bone regeneration of rabbit tibiae. Based on the experimental results, we applied this technique to the patients with femoral and humeral fractures in elderly patients, and obtained bone union.
Asunto(s)
Enfermedades Óseas/cirugía , Sustitutos de Huesos/uso terapéutico , Huesos/fisiología , Fosfatos de Calcio/uso terapéutico , Fracturas Óseas/cirugía , Adolescente , Anciano de 80 o más Años , Animales , Enfermedades Óseas/diagnóstico por imagen , Regeneración Ósea , Resorción Ósea/diagnóstico por imagen , Resorción Ósea/metabolismo , Sustitutos de Huesos/química , Sustitutos de Huesos/farmacología , Huesos/diagnóstico por imagen , Huesos/efectos de los fármacos , Huesos/cirugía , Fosfatos de Calcio/química , Fosfatos de Calcio/farmacología , Preescolar , Colágeno/farmacología , Colágeno/uso terapéutico , Femenino , Factor 2 de Crecimiento de Fibroblastos/química , Factor 2 de Crecimiento de Fibroblastos/farmacología , Factor 2 de Crecimiento de Fibroblastos/uso terapéutico , Fracturas Óseas/diagnóstico por imagen , Humanos , Procesamiento de Imagen Asistido por Computador/métodos , Inyecciones , Masculino , Persona de Mediana Edad , Osteoclastos/fisiología , Osteogénesis/efectos de los fármacos , Porosidad , Conejos , Proteínas Recombinantes/química , Proteínas Recombinantes/farmacología , Proteínas Recombinantes/uso terapéutico , Programas Informáticos , Fosfatasa Ácida Tartratorresistente/metabolismo , Tomografía Computarizada por Rayos X , Adulto JovenRESUMEN
This study showed that autoimmune arthritis induces especially severe osteoporosis in the periarticular region adjacent to inflamed joints, suggesting that arthritis increases the fragility fracture risk near inflamed joints, which is frequently observed in patients with RA. INTRODUCTION: Periarticular osteoporosis near inflamed joints is a hallmark of early rheumatoid arthritis (RA). Here we show that rheumatic inflammation deteriorates the bone quality and bone quantity of periarticular bone, thereby decreasing bone strength and toughness in a mouse model of RA. METHODS: Female BALB/c mice and SKG mice, a mutant mouse model of autoimmune arthritis on the BALB/c background, were used. At 12 weeks of age, BALB/c mice underwent either Sham surgery or bilateral ovariectomy (OVX), and SKG mice underwent intraperitoneal injection of mannan to induce arthritis. Eight weeks later, the mice were killed and the femurs and tibias were subjected to micro-computed tomography, Fourier transform infrared (FTIR) spectroscopic imaging, X-ray diffraction, histology, and mechanical testing. RESULTS: SKG mice developed significant trabecular bone loss in both the distal metaphysis of the femur and the lumbar vertebral body, but the extent of the bone loss was more severe in the distal metaphysis. Neither SKG nor OVX mice exhibited changes in the geometry and matrix properties of the diaphysis of the femur, whereas SKG mice, but not OVX mice, did exhibit changes in these properties in the distal metaphysis of the femur. Bone strength and fracture toughness of the distal metaphysis of the tibia adjacent to the inflamed ankle joint were significantly decreased in SKG mice. CONCLUSIONS: Autoimmune arthritis induces periarticular osteoporosis, characterized by deterioration of cortical bone geometry and quality as well as by trabecular bone loss, leading to severe bone fragility in periarticular bone adjacent to inflamed joints.
Asunto(s)
Artritis Experimental/complicaciones , Artritis Reumatoide/complicaciones , Osteoporosis/etiología , Animales , Artritis Experimental/diagnóstico por imagen , Artritis Experimental/fisiopatología , Artritis Reumatoide/diagnóstico por imagen , Artritis Reumatoide/fisiopatología , Fenómenos Biomecánicos , Densidad Ósea/fisiología , Resorción Ósea/diagnóstico por imagen , Resorción Ósea/etiología , Resorción Ósea/fisiopatología , Femenino , Fémur/diagnóstico por imagen , Fémur/patología , Fémur/fisiopatología , Ratones Endogámicos BALB C , Ratones Mutantes , Osteoporosis/diagnóstico por imagen , Osteoporosis/patología , Osteoporosis/fisiopatología , Ovariectomía , Índice de Severidad de la Enfermedad , Microtomografía por Rayos XRESUMEN
Lycopene supplementation decreases oxidative stress and exhibits beneficial effects on bone health, but the mechanisms through which it alters bone metabolism in vivo remain unclear. The present study aims to evaluate the effects of lycopene treatment on postmenopausal osteoporosis. Six-month-old female Wistar rats (n=264) were sham-operated (SHAM) or ovariectomized (OVX). The SHAM group received oral vehicle only and the OVX rats were randomized into five groups receiving oral daily lycopene treatment (mg/kg body weight per day): 0 OVX (control), 15 OVX, 30 OVX, and 45 OVX, and one group receiving alendronate (ALN) (2µg/kg body weight per day), for 12weeks. Bone densitometry measurements, bone turnover markers, biomechanical testing, and histomorphometric analysis were conducted. Micro computed tomography was also used to evaluate changes in microarchitecture. Lycopene treatment suppressed the OVX-induced increase in bone turnover, as indicated by changes in biomarkers of bone metabolism: serum osteocalcin (s-OC), serum N-terminal propeptide of type 1 collagen (s-PINP), serum crosslinked carboxyterminal telopeptides (s-CTX-1), and urinary deoxypyridinoline (u-DPD). Significant improvement in OVX-induced loss of bone mass, bone strength, and microarchitectural deterioration was observed in lycopene-treated OVX animals. These effects were observed mainly at sites rich in trabecular bone, with less effect in cortical bone. Lycopene treatment down-regulated osteoclast differentiation concurrent with up-regulating osteoblast together with glutathione peroxidase (GPx) catalase (CAT) and superoxide dismutase (SOD) activities. These findings demonstrate that lycopene treatment in OVX rats primarily suppressed bone turnover to restore bone strength and microarchitecture.